At a time when the pharmaceutical industry has reduced investment in the discovery
of new psychotropic medications, Zhang et al. (
1
) show how new approaches based on advances in brain imaging analysis methods can
facilitate drug discovery. Specifically, they identify the angiotensin II type 1 receptor
(AT1R) pathway as a promising novel target for the modulation of subjective fear experience
in humans.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological Psychiatry: Cognitive Neuroscience and NeuroimagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Angiotensin II regulates the neural expression of subjective fear in humans: A precision pharmaco-neuroimaging approach.Biol Psychiatry Cogn Neurosci Neuroimaging. 2023; 8: 262-270
- Two decades of new drug development for central nervous system disorders.Nat Rev Drug Discov. 2015; 14: 815-816
- The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.Psychopharmacology. 2021; 238: 2393-2403
- Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders.Pharmacol Ther. 2019; 204107402
- Using neuroscience to help understand fear and anxiety: A two-system framework.Am J Psychiatry. 2016; 173: 1083-1093
- Are emotions natural kinds?.Perspect Psychol Sci. 2006; 1: 28-58
- Limbic neuropeptidergic modulators of emotion and their therapeutic potential for anxiety and post-traumatic stress disorder.J Neurosci. 2021; 41: 901-910
- A distributed fMRI-based signature for the subjective experience of fear.Nat Commun. 2021; 12: 6643
Article info
Publication history
Accepted:
January 9,
2023
Received:
January 7,
2023
Identification
Copyright
© 2023 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Angiotensin II Regulates the Neural Expression of Subjective Fear in Humans: A Precision Pharmaco-Neuroimaging ApproachBiological Psychiatry: Cognitive Neuroscience and NeuroimagingVol. 8Issue 3
- PreviewRodent models and pharmacological neuroimaging studies in humans have been used to test novel pharmacological agents to reduce fear. However, these strategies are limited with respect to determining process-specific effects on the actual subjective experience of fear, which represents the key symptom that motivates patients to seek treatment. In this study, we used a novel precision pharmacological functional magnetic resonance imaging approach based on process-specific neuroaffective signatures to determine effects of the selective angiotensin II type 1 receptor (AT1R) antagonist losartan on the subjective experience of fear.
- Full-Text
- Preview
